Home » Drug Information » Recently Approved Drugs » 1997
Medical Areas: Endocrinology
Drug Information
The following information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Company: Knoll Pharmaceutical
Approval Status: Approved November 1997
Treatment Area: obesity
MERIDIA (sibutramine hydrochloride monohydrate) has been
approved for the management of obesity, including weight loss and
maintenance of weight loss, when used in conjunction with a
reduced-calorie diet.
Most side effects associated with MERIDIA are mild and transient
in nature, including dry mouth, headache, constipation, and
insomnia.
MERIDIA works in a different manner than other prescription
weight management medications. It is a neurotransmitter reuptake
inhibitor that merely enhances the body's normal function.
MERIDIA is not a releasing agent. It does not get inside the cells
to boost the release of neurotransmitters, such as serotonin.
Instead, as a reuptake inhibitor, MERIDIA works outside the cells
to stop neurotransmitters from being reabsorbed. MERIDIA works by
affecting natural chemicals in the brain involved in regulating
appetite--allowing them to act longer. The appetite control center
in the brain is believed to regulate the amount of food eaten
through feelings of hunger and fullness.